Abstract P6-17-22: Progression free survival (PFS) and overall survival (OS) of patients treated with trastuzumab emtansine (T-DM1) after previous treatment with pertuzumab in patients with advanced breast cancer (NCT02338167)
暂无分享，去创建一个
M. Beckmann | P. Fasching | T. Fehm | A. Schneeweiss | D. Wallwiener | H. Tesch | L. Haeberle | M. Untch | J. Huober | C. Thomssen | V. Müller | W. Janni | M. Lux | F. Taran | M. Wallwiener | S. Brucker | A. Hartkopf | P. Wimberger | R. Wuerstlein | J. Ettl | P. Hadji | D. Lüftner | B. Volz | C. Kurbacher | H. Kolberg | F. Overkamp | E. Belleville | W. Abenhardt | J. Lermann | M. Geberth | C. Hielscher